Adjuvant Capital

Offices: New York (United States), San Francisco (United States)

Stages: Series A, Series B, Series C

Markets: Life Sciences/Public Health Technologies:- High-burden & Neglected Infectious Diseases (HIV/AIDS, Tuberculosis, Malaria, Tropical Diseases, Pandemic Threats), Maternal & Child Health, Reproductive & Sexual Health